BartoszChmielowskiMDPhD

Oncology • Los Angeles, CA

Hematologic Oncology, Melanoma, Sarcoma

Associate Professor, Medicine, UCLA School of Medicine

Join to view full profile

Dr. Chmielowski is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Chmielowski's full profile

Already have an account?

Office
100 UCLA Medical Plaza
Suite 550
Los Angeles, CA 90095
Phone+1 310-794-4955

Fax+1 310-794-4955
Is this information wrong?

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
Medical College of GeorgiaResidency, Internal Medicine, 2001 - 2005
Wroclaw Medical UniversityClass of 1995

Certifications & Licensure

CA State Medical License 2004 - 2024
GA State Medical License 2004 - 2005
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Top Doctors:LA Area Castle Connolly, 2013
Top Doctors:Southern California Castle Connolly, 2012

Clinical Trials

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2007 Apr 01
Completed
Phase 2
A Phase I/II Study of Daily Oral Dosing With Temozolomide and Sunitinib Malate for 6 Weeks of an 8-Week Cycle in Patients With Metastatic and Unresectable Locally-Advanced Malignant Melanoma Start of enrollment: 2009 Apr 01
Study of Gene Modified Immune Cells in Patients With Advanced Melanoma Start of enrollment: 2009 Oct 13
Completed
Phase 2
Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma Start of enrollment: 2008 Dec 01
Completed
Phase 1
A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma Start of enrollment: 2011 Feb 01
Completed
Phase 2
Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. Start of enrollment: 2013 Jul 01
Terminated
Phase 1, Phase 2
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas Start of enrollment: 2014 Jan 01
Completed
Phase 3
LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma Start of enrollment: 2014 Jul 23
Completed
Phase 2
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions Start of enrollment: 2019 Jun 28
Recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers.
Algazi, A., Moon, J., Lao, C., Chmielowski, B., Kendra, K., Lewis, K., Gonzalez, R., Kim, K., Godwin, J., Curti, B., Latkovic-Taber, M., Lomeli, S., Gufford, B., Scump...> ;Cancer. 2024 Jan 23
7 citations
The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial.
Jason J Luke, Manish R Patel, George R Blumenschein, Erika Hamilton, Bartosz Chmielowski, Susanna V Ulahannan, Roisin M Connolly, Cesar A Santa-Maria, Jie Wang, Shakee...> ;Nature Medicine. 2023 Nov 1
Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue Sarcomas.
Steven Attia, Victor Villalobos, Nadia Hindi, Andrew J Wagner, Bartosz Chmielowski, Gerard J Oakley 3rd, Patrick M Peterson, Matteo Ceccarelli, Robin L Jones, Mark A D...> ;Cancers. 2023 Oct 6
2 citations
Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial.
Hong, D., Postow, M., Chmielowski, B., Sullivan, R., Patnaik, A., Cohen, E., Shapiro, G., Steuer, C., Gutierrez, M., Yeckes-Rodin, H., Ilaria, R., O'Connell, B., Peng,...> ;Clinical Cancer Research. 2023 Jun 13
38 citations
Neoantigen-targeted CD8T cell responses with PD-1 blockade therapy.
Cristina Puig-Saus, Barbara Sennino, Songming Peng, Clifford L Wang, Zheng Pan, Benjamin Yuen, Bhamini Purandare, Duo An, Boi B Quach, Diana Nguyen, Huiming Xia, Samee...> ;Nature. 2023 Mar 1
121 citations
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.
Sapna P Patel, Megan Othus, Yuanbin Chen, G Paul Wright Jr, Kathleen J Yost, John R Hyngstrom, Siwen Hu-Lieskovan, Christopher D Lao, Leslie A Fecher, Thach-Giao Truon...> ;The New England Journal of Medicine. 2023 Mar 2
ASO Visual Abstract: Lifelong Imaging Surveillance is Indicated for Patients with Primary Retroperitoneal Liposarcoma.
Mark A Eckardt, Danielle S Graham, Kyle D Klingbeil, Serena Y Lofftus, Tyler R McCaw, Mark J Bailey, Charles J Goldring, Joseph K Kendal, Brian E Kadera, Scott D Nelso...> ;Annals of Surgical Oncology. 2023 May 1
106 citations
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.
Atkins, M., Lee, S., Chmielowski, B., Tarhini, A., Cohen, G., Truong, T., Moon, H., Davar, D., O'Rourke, M., Stephenson, J., Curti, B., Urba, W., Brell, J., Funchain, ...> ;Journal of Clinical Oncology. 2023 Jan 10
5 citations
Lifelong Imaging Surveillance is Indicated for Patients with Primary Retroperitoneal Liposarcoma.
Mark A Eckardt, Danielle S Graham, Kyle D Klingbeil, Serena Y Lofftus, Tyler R McCaw, Mark J Bailey, Charles J Goldring, Joseph K Kendal, Brian E Kadera, Scott D Nelso...> ;Annals of Surgical Oncology. 2023 May 1
86 citations
Non-viral precision T cell receptor replacement for personalized cell therapy.
Susan P Foy, Kyle Jacoby, Daniela A Bota, Theresa Hunter, Zheng Pan, Eric Stawiski, Yan Ma, William Lu, Songming Peng, Clifford L Wang, Benjamin Yuen, Olivier Dalmas, ...> ;Nature. 2023 Mar 1
6 citations
A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastat...
Evan Rosenbaum, Rashmi Chugh, Christopher W Ryan, Mark Agulnik, Mohammed M Milhem, Suzanne George, Robin L Jones, Bartosz Chmielowski, Brian A Van Tine, Hussein Tawbi,...> ;European Journal of Cancer. 2022 Nov 1
3 citations
Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy.
Zev A Wainberg, Arun S Singh, Gottfried E Konecny, Kelly E McCann, J Randolph Hecht, Jonathan Goldman, Bartosz Chmielowski, Richard S Finn, Neil O'Brien, Erika Von Euw...> ;Clinical Cancer Research. 2023 Jan 4
2 citations
Retrospective analysis of adjuvant treatment for localized, operable uterine leiomyosarcoma.
Jomjit Chantharasamee, Karlton Wong, Pasathorn Potivongsajarn, Amir Qorbani, Neda Motamed, Sandra Brackert, Joshua Cohen, Bartosz Chmielowski, Anusha Kalbasi, Jianyu R...> ;Cancer Medicine. 2022 Aug 1
14 citations
Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.
Mrinal M Gounder, Albiruni Abdul Razak, Neeta Somaiah, Sant Chawla, Javier Martin-Broto, Giovanni Grignani, Scott M Schuetze, Bruno Vincenzi, Andrew J Wagner, Bartosz ...> ;Journal of Clinical Oncology. 2022 Aug 1
4 citations
CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burden.
Charles Peterfy, Yan Chen, Peter Countryman, Bartosz Chmielowski, Stephen P Anthony, John H Healey, Zev A Wainberg, Allen L Cohn, Geoffrey I Shapiro, Vicki L Keedy, Ar...> ;Future Oncology. 2022 Apr 1
19 citations
Adjuvant pembrolizumab versus interferon alfa-2b or ipilimumab in resected high-risk melanoma.
Kenneth F. Grossmann, Megan Othus, Sapna Pradyuman Patel, Ahmad A. Tarhini, Vernon K. Sondak, Michael V. Knopp, Teresa M. Petrella, Thach-Giao Truong, Nikhil I. Khusha...> ;Cancer Discovery. 2021 Nov 11
8 citations
Results from Phase 1 Extension Study Assessing Pexidartinib Treatment in 6 cohorts with Solid Tumors including TGCT, and Abnormal CSF1 Transcripts in TGCT
William D. Tap, Arun S. Singh, Stephen P. Anthony, Mike Sterba, Chao Zhang, John H. Healey, Bartosz Chmielowski, Allen Lee Cohn, Geoffrey I. Shapiro, Vicki L. Keedy, Z...> ;Clinical Cancer Research. 2021 Oct 29
2 citations
Management of Clitoral Melanoma Presenting as an Exophytic Clitoral Mass: A Case Report and Review of the Literature
Alec Szlachta-McGinn, Bartosz Chmielowski, Yuna Kang, Steven S. Raman, Sanaz Memarzadeh> ;Current Oncology. 2021 Oct 21
17 citations
A Randomized Phase 2 Study Of Nivolumab Monotherapy Or Nivolumab Combined with Ipilimumab In Patients with Advanced Gastrointestinal Stromal Tumors
Arun S. Singh, J. Randolph Hecht, Lee S. Rosen, Zev A. Wainberg, Xiaoyan Wang, Michael Douek, Anahis Hagopian, Rachel Andes, Lauren Sauer, Sandra Brackert, Warren Chow...> ;Clinical Cancer Research. 2021 Aug 18
58 citations
Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma.
Antoni Ribas, Theresa Medina, John M. Kirkwood, Yousef Zakharia, Rene Gonzalez, Diwakar Davar, Bartosz Chmielowski, Katie M. Campbell, Riyue Bao, Heather Kelley, Aaron...> ;Cancer Discovery. 2021 Jul 29
10 citations
Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma.
Mrinal M. Gounder, Albiruni Ryan Abdul Razak, Adrienne M Gilligan, Hoyee Leong, Xiwen Ma, Neeta Somaiah, Sant P. Chawla, Javier Martin-Broto, Giovanni Grignani, Scott ...> ;Future Oncology. 2021 Apr 15
136 citations
Melanoma: Cutaneous, Version 2.2021 Featured Updates to the NCCN Guidelines
Susan M. Swetter, John A. Thompson, Mark R. Albertini, Christopher A. Barker, Joel M. Baumgartner, Genevieve M. Boland, Bartosz Chmielowski, Dominick J. DiMaio, Alison...> ;Journal of the National Comprehensive Cancer Network. 2021 Apr 1
51 citations
Erratum: Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma (Cancer Cell (2020) 38(4) (500–515.e3), (S15356108...
, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , > ;Cancer Cell. 2021 Jan 11
3 citations
Translating Knowledge About the Immune Microenvironment of Gastrointestinal Stromal Tumors into Effective Clinical Strategies.
Jomjit Chantharasamee, Jacob J. Adashek, Karlton Wong, Mark A. Eckardt, Bartosz Chmielowski, Sarah M. Dry, Fritz C. Eilber, Arun S. Singh> ;Current Treatment Options in Oncology. 2021 Jan 5
306 citations
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.
Patrick A. Ott, Siwen Hu-Lieskovan, Bartosz Chmielowski, Ramaswamy Govindan, Aung Naing, Nina Bhardwaj, Kim Margolin, Mark M. Awad, Matthew D. Hellmann, Jessica J. Lin...> ;Cell. 2020 Oct 15
Join now to see all

Press Mentions

ASCO 2022 | Ascentage Pharma Releases Updated Results Demonstrating the Therapeutic Potential of Alrizomadlin (APG-115) plus Pembrolizumab in Patients with Solid Tumors Who Progressed on ImmunotherapiesJune 7th, 2022
Reversing Resistance to PD-1 Inhibitors with Combination Immunotherapy in Patients with Advanced MelanomaApril 8th, 2022
Immunocore Announces Upcoming Presentations at the European Society for Medical Oncology (ESMO) Congress 2021September 13th, 2021
Join now to see all